Wells Fargo & Company Phathom Pharmaceuticals, Inc. Transaction History

Wells Fargo & Company

$468 Billion
Q2 2025

A detailed history of Wells Fargo & Company transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 46,678 shares of PHAT stock, worth $541,931. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,678

Previous 28,425 64.21%

Holding current value

$541,931

Previous $178,000 151.12%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$2.29 - $10.9 $41,799 - $198,957	18,253 Added 64.21%	46,678 $447,000
Q1 2025 May 13, 2025	BUY	$4.22 - $7.74 $12,275 - $22,515	2,909 Added 11.4%	28,425 $178,000
Q4 2024 Feb 12, 2025	BUY	$7.45 - $18.94 $55,591 - $141,330	7,462 Added 41.33%	25,516 $207,000
Q3 2024 Nov 13, 2024	BUY	$10.25 - $19.5 $7,574 - $14,410	739 Added 4.27%	18,054 $326,000
Q2 2024 Aug 13, 2024	BUY	$8.97 - $12.05 $51,218 - $68,805	5,710 Added 49.2%	17,315 $178,000
Q1 2024 May 10, 2024	BUY	$6.21 - $11.05 $4,440 - $7,900	715 Added 6.57%	11,605 $123,000
Q4 2023 Feb 09, 2024	BUY	$6.99 - $10.71 $25,275 - $38,727	3,616 Added 49.71%	10,890 $99,000
Q3 2023 Nov 13, 2023	SELL	$10.26 - $15.7 $23,844 - $36,486	-2,324 Reduced 24.21%	7,274 $75,000
Q2 2023 Aug 15, 2023	BUY	$7.28 - $14.32 $35,468 - $69,767	4,872 Added 103.09%	9,598 $137,000
Q1 2023 May 12, 2023	BUY	$6.19 - $12.36 $29,253 - $58,413	4,726 New	4,726 $33,000
Q3 2022 Nov 14, 2022	SELL	$6.46 - $12.11 $1,240 - $2,325	-192 Reduced 32.05%	407 $5,000
Q2 2022 Aug 12, 2022	SELL	$6.2 - $15.5 $6,237 - $15,593	-1,006 Reduced 62.68%	599 $5,000
Q1 2022 May 16, 2022	SELL	$11.55 - $20.06 $83,021 - $144,191	-7,188 Reduced 81.75%	1,605 $22,000
Q4 2021 Feb 14, 2022	BUY	$17.83 - $33.15 $156,779 - $291,487	8,793 New	8,793 $173,000
Q2 2021 Aug 16, 2021	SELL	$32.66 - $39.87 $115,191 - $140,621	-3,527 Closed	0 $0
Q1 2021 May 13, 2021	SELL	$33.86 - $48.68 $262,821 - $377,854	-7,762 Reduced 68.76%	3,527 $132,000
Q4 2020 Feb 09, 2021	BUY	$33.22 - $50.26 $88,431 - $133,792	2,662 Added 30.86%	11,289 $375,000
Q3 2020 Nov 05, 2020	SELL	$29.24 - $40.19 $84,211 - $115,747	-2,880 Reduced 25.03%	8,627 $316,000
Q2 2020 Aug 13, 2020	BUY	$25.06 - $54.6 $130,512 - $284,356	5,208 Added 82.68%	11,507 $379,000
Q1 2020 May 14, 2020	BUY	$24.65 - $42.83 $155,270 - $269,786	6,299 New	6,299 $163,000

Others Institutions Holding PHAT

# of Institutions

138

Shares Held

60.5M

Call Options Held

1.35M

Put Options Held

1.19M

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $455M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Phathom Pharmaceuticals, Inc. Transaction History